The biological relevance of virus neutralisation sites for virulence and vaccine protection in the guinea pig model of foot-and-mouth disease
- PMID: 9683571
- DOI: 10.1006/viro.1998.9175
The biological relevance of virus neutralisation sites for virulence and vaccine protection in the guinea pig model of foot-and-mouth disease
Abstract
Five neutralisation epitopes have been defined for the O1 Kaufbeuren strain of foot-and-mouth disease virus (FMDV) by neutralising murine monoclonal antibodies (Mabs). A mutant virus which is resistant to all these Mabs also resists neutralisation by bovine polyclonal sera, and this characteristic was exploited in the current study to investigate the biological relevance of neutralisation sites in FMDV virulence and vaccine protection. The five site neutralisation-resistant mutant was shown to be as pathogenic as wild-type virus in the guinea pig model of FMD. Guinea pigs were protected in cross-challenge studies from virulent wild-type and mutant viruses using either wild-type or mutant 146S antigen as inactivated whole virus vaccine. Furthermore, hyperimmune sera raised to either wild-type or mutant antigen offered passive protection against wild-type challenge, in spite of the serum raised against the mutant antigen having minimal neutralising activity in vitro. These results imply that virus neutralisation, at least as defined by the in vitro assay, may not play an essential role in the mechanism of immunity induced by whole inactivated FMDV vaccines.
Similar articles
-
Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate.Virology. 1999 Oct 25;263(2):496-506. doi: 10.1006/viro.1999.9940. Virology. 1999. PMID: 10544121
-
Escape mutants of foot-and-mouth disease virus selected by monoclonal antibodies directed to a trypsin-sensitive neutralization epitope.Acta Virol. 1997 Jun;41(3):131-8. Acta Virol. 1997. PMID: 9385400
-
Orally delivered foot-and-mouth disease virus capsid protomer vaccine displayed on T4 bacteriophage surface: 100% protection from potency challenge in mice.Vaccine. 2008 Mar 10;26(11):1471-81. doi: 10.1016/j.vaccine.2007.12.053. Epub 2008 Jan 24. Vaccine. 2008. PMID: 18289743
-
Selection of foot and mouth disease vaccine strains--a review.Rev Sci Tech. 2005 Dec;24(3):981-93. Rev Sci Tech. 2005. PMID: 16642769 Review.
-
Strategy for producing new foot-and-mouth disease vaccines that display complex epitopes.J Biotechnol. 1996 Jan 26;44(1-3):83-9. doi: 10.1016/0168-1656(95)00090-9. J Biotechnol. 1996. PMID: 8717390 Review.
Cited by
-
Novel antibody binding determinants on the capsid surface of serotype O foot-and-mouth disease virus.J Gen Virol. 2014 May;95(Pt 5):1104-1116. doi: 10.1099/vir.0.060939-0. Epub 2014 Feb 28. J Gen Virol. 2014. PMID: 24584474 Free PMC article.
-
Challenges and prospects for the control of foot-and-mouth disease: an African perspective.Vet Med (Auckl). 2014 Oct 3;5:119-138. doi: 10.2147/VMRR.S62607. eCollection 2014. Vet Med (Auckl). 2014. PMID: 32670853 Free PMC article. Review.
-
Tracking the Antigenic Evolution of Foot-and-Mouth Disease Virus.PLoS One. 2016 Jul 22;11(7):e0159360. doi: 10.1371/journal.pone.0159360. eCollection 2016. PLoS One. 2016. PMID: 27448206 Free PMC article.
-
Determining the epitope dominance on the capsid of a serotype SAT2 foot-and-mouth disease virus by mutational analyses.J Virol. 2014 Aug;88(15):8307-18. doi: 10.1128/JVI.00470-14. Epub 2014 May 14. J Virol. 2014. PMID: 24829347 Free PMC article.
-
Optimized Adenoviral Vector That Enhances the Assembly of FMDV O1 Virus-Like Particles in situ Increases Its Potential as Vaccine for Serotype O Viruses.Front Microbiol. 2020 Nov 4;11:591019. doi: 10.3389/fmicb.2020.591019. eCollection 2020. Front Microbiol. 2020. PMID: 33250878 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources